Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Esophageal cancer is a significant health concern with limited effective treatments.
• Specificity protein (Sp) transcription factors and their downstream targets are implicated in cancer progression.
• Hepatocyte growth factor receptor (c-Met) is overexpressed in esophageal cancer and represents a potential drug target.

Purpose of the Study:

• To investigate the effects of tolfenamic acid (TA) on esophageal cancer cells.
• To explore the role of Sp transcription factors and c-Met in TA's anti-cancer activity.
• To evaluate TA as a potential chemotherapeutic agent for esophageal cancer.

Main Methods:

• Cell proliferation assays using SEG-1 and BIC-1 esophageal cancer cell lines.
• Annexin V staining to assess apoptosis.
• Western blotting and RNA interference to analyze Sp transcription factors (Sp1, Sp3, Sp4) and c-Met expression.
• In vivo xenograft studies in athymic nude mice.

Main Results:

• Tolfenamic acid inhibited esophageal cancer cell proliferation and induced apoptosis.
• TA decreased the expression of Sp1, Sp3, Sp4, and their regulated genes, including cyclin D1, vascular endothelial growth factor, and survivin.
• TA reduced c-Met expression, and c-Met was identified as an Sp-regulated gene.
• In vivo, TA treatment suppressed tumor growth, increased apoptosis, and decreased Sp1 and c-Met levels in tumors.

Conclusions:

• Tolfenamic acid exhibits anti-cancer properties against esophageal cancer cells.
• Downregulation of Sp transcription factors and c-Met by TA represents a novel mechanism for esophageal cancer therapy.
• TA demonstrates potential as a chemotherapeutic agent for esophageal cancer treatment.